Search results
Results from the WOW.Com Content Network
This is the list of Schedule II controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required for substances to be placed in this schedule: [ 2 ]
Carbonate derivatives of 14β-hydroxycodeine "viz., 14β-hydroxy-6-O-(methoxycarbonyl)codeine, 6-O-methoxycarbonyl-14β-(methoxycarbonyloxy)codeine, and 14β-acetoxy-6-O-methoxy-carbonylcodeine, potential substrates for ring C modification in morphinane (sic) alkaloids, were synthesized for the first time."
Titan's principal asset is Probuphine, [5] [6] a slow-release implant formulation of buprenorphine [7] for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. [8] It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. [6]
Apr. 11—AUSTIN — Texas Comptroller Glenn Hegar announced Thursday that the Opioid Abatement Fund Council's (OAFC or the Council) Naloxone Distribution Grant Opportunity is open for applications.
McKinsey & Company consulting firm has agreed to pay $650 million to settle a federal investigation into its work to help opioids manufacturer Purdue Pharma boost the sales of the highly addictive ...
Drug companies, wholesalers and pharmacies have agreed to pay a total of more than $50 billion to settle lawsuits filed by state, local and Native American tribal governments and others that ...
Fentanyl is a highly potent synthetic piperidine opioid primarily used as an analgesic.It is 30 to 50 times more potent than heroin and 100 times more potent than morphine; [11] its primary clinical utility is in pain management for cancer patients and those recovering from painful surgeries.
Endo is one of the companies named in lawsuits by the states of Ohio, [42] Missouri and Mississippi [43] as responsible for the US opioid epidemic. Its 10-K statement indicates that a majority of the company's US revenue in 2016 was derived from the sale of prescription pain killers, predominantly opioids. [44]